Targeting EGFR has been shown to promise in the treatment of many cancers, such as breast, lung cancer and glioblastoma, through PI3K-AKT and EGFR-RAS-RAF [[54], [55], [56], [57]]. Here, AKT1 is linked to lung carcinoma.